Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
| 0.533 | |
| 0.5569 | |
| - | |
| 0.5698 | |
| 0.531 | |
| 0.4772-5.75 | |
| 2 302 K | |
| 3 980 K | |
| 0 | |
| -0.39 | |
| 2.039 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoin...
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and or...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
